Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts
by Tristan Rich · The Markets DailyKura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $26.8571.
Several research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Finally, Mizuho reduced their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th.
Read Our Latest Stock Analysis on Kura Oncology
Kura Oncology Price Performance
Shares of NASDAQ KURA opened at $8.13 on Wednesday. The stock has a market cap of $718.12 million, a P/E ratio of -2.56 and a beta of 0.22. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $12.49. The stock has a 50 day moving average of $8.41 and a two-hundred day moving average of $9.49. The company has a current ratio of 6.06, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06.
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). The business had revenue of $17.34 million for the quarter, compared to analysts’ expectations of $34.71 million. Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%. On average, research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.
Insider Buying and Selling
In other news, insider Brian T. Powl sold 6,414 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $54,262.44. Following the transaction, the insider owned 183,275 shares of the company’s stock, valued at approximately $1,550,506.50. The trade was a 3.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 8,180 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $69,202.80. Following the sale, the insider directly owned 267,274 shares of the company’s stock, valued at approximately $2,261,138.04. This represents a 2.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 36,068 shares of company stock worth $305,135. 6.40% of the stock is currently owned by company insiders.
Institutional Trading of Kura Oncology
Hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its stake in shares of Kura Oncology by 5.7% during the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after acquiring an additional 459,422 shares during the period. Vanguard Group Inc. lifted its position in Kura Oncology by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after purchasing an additional 39,105 shares during the period. Armistice Capital LLC boosted its holdings in Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after purchasing an additional 264,000 shares in the last quarter. State Street Corp boosted its holdings in Kura Oncology by 47.5% in the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter. Finally, EcoR1 Capital LLC increased its position in Kura Oncology by 59.1% during the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after purchasing an additional 1,559,702 shares during the period.
About Kura Oncology
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.